Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 12, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Ivabradine Tablets, 5 mg and 7.5 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 12, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Ivabradine Tablets, 5 mg and 7.5 mg".